药物性肝损伤的生物标志物研究进展

摘要/Abstract

摘要： 由于药物性肝损伤(DILI)发病机制不清,病理生理学特点不明,其诊断仍基于排除其他肝损伤原因。目前临床仍然将丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)和总胆红素(TBil)等传统肝脏生物标志物作为肝损伤的临床指标, 仍缺乏特异性的DILI生物标志物。本文将传统的临床肝损伤指标,潜在的基于蛋白组学、转录组学、药物基因组学和代谢组学等DILI新型生物标志物做一阐述。

关键词: 药物性肝损伤, 临床诊断, 生物标志物, 组学研究

李应懿, 陈挥昂, 谢青, 赖荣陶. 药物性肝损伤的生物标志物研究进展[J]. 肝脏, 2022, 27(12): 1258-1263.

参考文献

[1] Rafter I, Graberg T, Kotronen A, et al. Isoform-specific alanine aminotransferase measurement can distinguish hepatic from extrahepatic injury in humans. Int J Mol Med, 2012,30:1241-1249.
[2] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南. 中华肝脏病杂志,2015,23:810-820.
[3] Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf,2011,34:243-252.
[4] Mosedale M, Watkins PB. Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther,2017,101:469-480.
[5] Chen M, Borlak J, Tong W. A Model to predict severity of drug-induced liver injury in humans. Hepatology,2016,64:931-940.
[6] Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology,2013,58:777-787.
[7] Harrill AH, Roach J, Fier I, et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 2012;92:214-20.
[8] Metushi IG, Zhu X, Uetrecht J. D-penicillamine-induced granulomatous hepatitis in brown Norway rats. Mol Cell Biochem 2014;393:229-35.
[9] Antoine DJ, Williams DP, Kipar A, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci,2009,112:521-531.
[10] Stutchfield BM, Antoine DJ, Mackinnon AC, et al. CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure. Gastroenterology,2015,149:1896-1909 e14.
[11] Bechmann LP, Jochum C, Kocabayoglu P, et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol, 2010,53:639-647.
[12] Rutherford A, King LY, Hynan LS, et al. Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology,2012,143:1237-1243.
[13] Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology, 2019,69:760-773.
[14] Ward J, Kanchagar C, Veksler-Lublinsky I, et al. Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc Natl Acad Sci U S A,2014,111:12169-12174.
[15] Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int,2014,34:367-378.
[16] Cho YE, Kim SH, Lee BH, et al. Circulating Plasma and Exosomal microRNAs as Indicators of Drug-Induced Organ Injury in Rodent Models. Biomol Ther (Seoul),2017,25:367-373.
[17] Koberle V, Pleli T, Schmithals C, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS One,2013,8:e75184.
[18] Kim SH, Naisbitt DJ. Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy Asthma Immunol Res,2016,8:3-11.
[19] Clinton JW, Kiparizoska S, Aggarwal S, et al. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Saf,2021,44:1125-1149.
[20] Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol,2011,8:202-211.
[21] Li C, Rao T, Chen X, et al. HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans. Hepatology,2019,70:346-357.
[22] Oda S, Uchida Y, Aleo MD, et al. An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol,2021,95:149-168.
[23] Huai C, Wei Y, Li M, et al. Genome-Wide Analysis of DNA Methylation and Antituberculosis Drug-Induced Liver Injury in the Han Chinese Population. Clin Pharmacol Ther,2019,106:1389-1397.
[24] Winnike JH, Li Z, Wright FA, et al. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther,2010,88:45-51.
[25] Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol,2011,54:666-673.
[26] Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res,2019,49:105-110.
[27] Delgado A, Stewart S, Urroz M, et al. Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. J Clin Med,2021,10.
[28] Niijima K, Niijima Y, Okada S, et al. Drug-induced Liver injury Caused by Ipragliflozin Administration with Causality Established by a Positive Lymphocyte Transformation Test (LTT) and the Roussel Uclaf Causality Assessment Method (RUCAM): A Case Report. Ann Hepatol, 2017,16:308-311.
[29] Rodriguez A, Garcia-Garcia I, Martinez de Soto L, et al. Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study. Front Pharmacol,2022,13:819589.
[30] Mantani N, Kogure T, Sakai S, et al. Incidence and clinical features of liver injury related to Kampo (Japanese herbal) medicine in 2,496 cases between 1979 and 1999: problems of the lymphocyte transformation test as a diagnostic method. Phytomedicine,2002,9:280-287.